The Age of Psychopharmacology began with a brilliant rise in the 1950s, when for the first time science entered the study of drugs that affect the brain and mind. But, esteemed historian Edward Shorter argues that there has been a recent fall, as the field has seen its drug offerings impoverished and its diagnoses distorted by the "Diagnostic and Statistical Manual of Mental Disorders." The new drugs, such as Prozac, have been less effective than the old. The new diagnoses, such as "major depression," have strayed increasingly from the real disorders of most patients. Behind this disaster has been the invasion of the field by the pharmaceutical industry. This invasion has paid off commercially but not scientifically: There have been no new classes of psychiatry drugs in the last thirty years. Given that psychiatry's diagnoses and therapeutics have largely failed, the field has greatly declined from earlier days. Based on extensive research discovered in litigation, Shorter provides a historical perspective of change and decline over time, concluding that the story of the psychopharmacology is a story of a public health disaster.

Treatment with drugs is fundamental to modern therapy of psychiatric disorders. The number of disorders responsive to drug treatment is increasing, reflecting the extensive synthesis of novel compounds and the greater understanding of the aetiology of the disorders. This third edition provides new and updated material, including an additional chapter on clinical trials and their importance in assessing the efficacy and safety of psychotropic drugs. As molecular biology and imaging techniques are of increasing importance to basic and clinical neuroscience, these areas have also been extended to illustrate their relevance to our understanding of psychopharmacology. This book is essential reading for undergraduates in pharmacology and the neurosciences, postgraduate neuropharmacologists, psychiatrists in training and in practice and medical researchers. Reviews of the Second Edition "...this text is eminently readable, well researched, and probably the best of its kind. The book is well worth buying and anyone who claims to know anything about psychopharmacology will be expected to have a heavily annotated copy." Irish Journal of Psychological Medicine "...[this is] a very good book, especially suited to those interested in psychopharmacologic research and psychiatric residency in training." Journal of Chemical Neuroanatomy

Neuropsychopharmacology reviews the principles of pharmacology with a focus on the central nervous system and autonomic nervous system. Beyond autonomic and central nervous system pharmacology, this volume uniquely discusses psychiatric disorders and the pharmacological interventions that are available for conditions including depression, schizophrenia and anxiety disorders. With a focus on these specific body systems, readers will see end-of-chapter questions that offer real-world case studies, as well as multiple-choice questions for further learning. Beneficial features and content also include two extensive examination tests, which each contain 100 questions for better learning or to be used in teaching, and a glossary. Helpful appendices cover high-alert medications and toxicology effects on the nervous system. Each chapter will contain classifications of medications, pharmacokinetics, mechanism of action, clinical indications and toxicities. - Describes pharmacology principles pertaining to the central and autonomic nervous system - Identifies pharmacological interventions for psychiatric disorders including current evidence-based interventions for depression, schizophrenia and anxiety disorders - Features chapter outlines, end-of-chapter questions, real-world case studies and examinations for deeper learning or teaching

The remarkable untold story of a miracle drug, the forgotten pioneer who discovered it, and the fight to bring lithium to the masses. The DNA double helix, penicillin, the X-ray, insulin—these are routinely cited as some of the most important medical discoveries of the twentieth century. And yet, the 1949 discovery of lithium as a cure for bipolar disorder is perhaps one of the most important—yet largely unsung—breakthroughs of the modern era. In Lithium, Walter Brown, a practicing psychiatrist and professor at Brown, reveals two unlikely success stories: that of John Cade, the physician whose discovery would come to save an untold number of lives and launch a pharmacological revolution, and that of a miraculous metal rescued from decades of stigmatization. From insulin comas and lobotomy to incarceration to exile, Brown chronicles the troubling history of the diagnosis and (often ineffective) treatment of bipolar disorder through the centuries, before the publication of a groundbreaking research paper in 1949. Cade’s “Lithium Salts in the Treatment of Psychotic Excitement” described, for the first time, lithium’s astonishing efficacy at both treating and preventing the recurrence of manic-depressive episodes, and would eventually transform the lives of patients, pharmaceutical researchers, and practicing physicians worldwide. And yet, as Brown shows, it would be decades before lithium would overcome widespread stigmatization as a dangerous substance, and the resistance from the pharmaceutical industry, which had little incentive to promote a naturally occurring drug that could not be patented. With a vivid portrait of the story’s unlikely hero, John Cade, Brown also describes a devoted naturalist who, unlike many modern medical researchers, did not benefit from prestigious research training or big funding sources (Cade’s “laboratory” was the unused pantry of an isolated mental hospital). As Brown shows, however, these humble conditions were the secret to his historic success: Cade was free to follow his own restless curiosity, rather than answer to an external funding source. As Lithium makes tragically clear, medical research—at least in America—has transformed in such a way that serendipitous discoveries like Cade’s are unlikely to occur ever again. Recently described by the New York Times as the “Cinderella” of psychiatric drugs, lithium has saved countless of lives and billions of dollars in healthcare costs. In this revelatory biography of a drug and the man who fought for its discovery, Brown crafts a captivating picture of modern medical history—revealing just how close we came to passing over this extraordinary cure.

Do antidepressants work, or are they glorified dummy pills? How can we tell? In Ordinarily Well, the celebrated psychiatrist and author Peter D. Kramer examines the growing controversy about the popular medications. A practicing doctor who trained as a psychotherapist and worked with pioneers in psychopharmacology, Kramer combines moving accounts of his patients’ dilemmas with an eye-opening history of drug research to cast antidepressants in a new light. Kramer homes in on the moment of clinical decision making: Prescribe or not? What evidence should doctors bring to bear? Using the wide range of reference that readers have come to expect in his books, he traces and critiques the growth of skepticism toward antidepressants. He examines industry-sponsored research, highlighting its shortcomings. He unpacks the “inside baseball” of psychiatry—statistics—and shows how findings can be skewed toward desired conclusions. Kramer never loses sight of patients. He writes with empathy about his clinical encounters over decades as he weighed treatments, analyzed trial results, and observed medications’ influence on his patients’ symptoms, behavior, careers, families, and quality of life. He updates his prior writing about the nature of depression as a destructive illness and the effect of antidepressants on traits like low self-worth. Crucially, he shows how antidepressants act in practice: less often as miracle cures than as useful, and welcome, tools for helping troubled people achieve an underrated goal—becoming ordinarily well.

"The 2nd edition of this book was edited by David King and published in 2004. Since then there have been major advances in psychopharmacology in terms of new medications coming to the market, increased understanding of the mechanisms of drug action and new data on the efficacy, tolerability, safety and clinical effectiveness of a range of medications. Partly as a result, clinical guidelines for many psychiatric disorders have altered. As such, a new edition of this textbook was essential and we were delighted when the College approached us to edit the 3rd edition. This was a major endeavor that was only possible with the commitment and expertise of the authors"--

Psychotropic agents have been effective for the treatment of the emotional, and cognitive symptoms of serious psychiatric disorders. At the same time, the availability of such agents raises questions about the appropriate use of what might be termed 'smart pills', 'happy pills', or 'pep pills'. This volume argues that developments in modern psychopharmacology raise a range of important philosophical questions, and may ultimately change the way we think about ourselves. It provides a framework for addressing important philosophical issues in psychiatry and psychopharmacology. The approach is a naturalistic one, drawing on theory and data from modern cognitive-affective neuroscience and attempts to address objective and subjective aspects of psychiatric disorders, to integrate our knowledge of mechanisms and meanings, and to provide a balanced view of the good and the bad of psychotropics.